News & Updates

Original New Drug Application Approvals by US FDA (16-30 November 2024)

06 Dec 2024

New drug applications approved by US FDA as of 16-30 November 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 November 2024)

06 Dec 2024

Crowding, mobility predict TB infection among kids

04 Dec 2024

A high prevalence of tuberculosis (TB) infection is seen among children and adolescents residing in rural Uganda, a study has found. Crowding and mobility are some of the factors associated with TB risk.

Crowding, mobility predict TB infection among kids

04 Dec 2024

Survivors of childhood cancer at risk of keratinocyte carcinoma

03 Dec 2024

Keratinocyte carcinomas (KC) remain a significant burden among childhood cancer survivors (CCS), but there are predictable risk factors that can guide screening, according to a study.

Survivors of childhood cancer at risk of keratinocyte carcinoma

03 Dec 2024

Nomogram identifies burned children at risk of infections

03 Dec 2024 by

A newly developed nomogram demonstrates its ability to predict the risk of healthcare-associated infections (HAIs) in burned children. This prediction model is based on factors such as larger burns, longer length of stay (LOS), and use of central venous catheter (CVC), among others.

Nomogram identifies burned children at risk of infections

03 Dec 2024

Meropenem-vaborbactam on par with ceftazidime-avibactam for survival in CRE infections, with an edge against resistance emergence

30 Nov 2024 by

The likelihood of survival at 30 days among patients with CRE infections is similar for those who receive ceftazidime-avibactam or meropenem-vaborbactam. However, recurrent infections and the emergence of resistance are observed less frequently with the latter carbapenem/BLI combination, as suggested by a prospective observational study presented at IDWeek 2024

Meropenem-vaborbactam on par with ceftazidime-avibactam for survival in CRE infections, with an edge against resistance emergence

30 Nov 2024

Widespread “test-and-treat” practices raise concerns over H. pylori management in children

29 Nov 2024 by

For the screening and diagnosis of paediatric Helicobacter pylori infection at a tertiary centre in Singapore, endoscopies are often skipped in favour of a “test-and-treat” approach based on noninvasive testing, a practice that deviates from recommended protocols.

Widespread “test-and-treat” practices raise concerns over H. pylori management in children

29 Nov 2024

Flu shots reduce spread of infection within households

29 Nov 2024

Influenza vaccination appears to mitigate the risk of secondary infections among unvaccinated household contacts, according to a study.

Flu shots reduce spread of infection within households

29 Nov 2024

Healthy prenatal diet linked to better infant growth

27 Nov 2024

Following a healthy prenatal diet, as outlined by the US Dietary Guidelines, helps reduce the likelihood of rapid or slow infant growth, both of which are risk factors for obesity, according to a study.

Healthy prenatal diet linked to better infant growth

27 Nov 2024

Add-on intrauterine misoprostol lowers PPH risk during caesarean delivery

27 Nov 2024 by

Adding intrauterine misoprostol to oxytocin significantly reduced the incidence of postpartum haemorrhage (PPH) in women who underwent caesarean section (CS) compared with oxytocin alone, according to a study presented at RCOG 2024.

Add-on intrauterine misoprostol lowers PPH risk during caesarean delivery

27 Nov 2024

Nirmatrelvir/ritonavir for COVID-19 in children passes safety test

23 Nov 2024 by

Treatment of symptomatic COVID-19 with nirmatrelvir/ritonavir in children at least 6 years of age who are at risk of progression to severe disease appears to be safe and well-tolerated, with pharmacokinetic data from the open-label phase 2/3 EPIC-Peds* study indicating suitable dosing regimens for two distinct weight categories of this population.

Nirmatrelvir/ritonavir for COVID-19 in children passes safety test

23 Nov 2024

News & Updates

Filter by Specialty:

Specialty:

Original New Drug Application Approvals by US FDA (16-30 November 2024)

Original New Drug Application Approvals by US FDA (16-30 November 2024)

Crowding, mobility predict TB infection among kids

Crowding, mobility predict TB infection among kids

Survivors of childhood cancer at risk of keratinocyte carcinoma

Survivors of childhood cancer at risk of keratinocyte carcinoma

Nomogram identifies burned children at risk of infections

Nomogram identifies burned children at risk of infections

Meropenem-vaborbactam on par with ceftazidime-avibactam for survival in CRE infections, with an edge against resistance emergence

Meropenem-vaborbactam on par with ceftazidime-avibactam for survival in CRE infections, with an edge against resistance emergence

Widespread “test-and-treat” practices raise concerns over H. pylori management in children

Widespread “test-and-treat” practices raise concerns over H. pylori management in children

Flu shots reduce spread of infection within households

Flu shots reduce spread of infection within households

Healthy prenatal diet linked to better infant growth

Healthy prenatal diet linked to better infant growth

Add-on intrauterine misoprostol lowers PPH risk during caesarean delivery

Add-on intrauterine misoprostol lowers PPH risk during caesarean delivery

Nirmatrelvir/ritonavir for COVID-19 in children passes safety test

Nirmatrelvir/ritonavir for COVID-19 in children passes safety test